Abstract:Objectives Diabetes-induced impairment of collateral formation in ischaemic myocardium has been demonstrated both in experimental and clinical studies, which may contribute to unfavorableprognosis among diabetic individuals. However, the underlying mechanism remains to be defined. Endothelial cell (EC) is thought to be one of the important elements in the development and maturation of coronary collaterals. Since ERK5 is a novel regulator of angiogenesis and closely related with VEGF, in present study we aim to determine whether ERK5 exerts a causative effect on advanced glycation end products (AGEs)-induced impairment of angiogenic capacity in cardiac ECs under hypoxia condition, and to identify the down streamtarget molecule. Methods Cardiac ECs were isolated from left ventricle of Sprague-Dawley rats with a enzyme digestion procedure described in our previous publications. Cells were treated with or without AGEs and then exposed to hypoxia or normoxia. Proliferation, migration and tube-forming of endothelial cells were detected by MTT, Transwell and Matrigel assay respectively. Protein of interest were further validated using ELISA and Western-blot techniques. Results Hypoxia promoted proliferation, migration and tube-forming capacity in cardiac ECs, which was inhibited significantly by combined administration of AGEs. Incubation with AGEs induced decrease of VEGF secretion and increase of ERK5 phosphorylation after hypoxia stimulation. XMD8-92, a inhibitor of ERK5 phosphorylation, treatment caused elevation of VEGF secretion, and counteracted AGEs-induced impairment of angiogenic capacity in cardiac ECs under hypoxia condition, which has a similar effect with supplementation of exogenous VEGF. Conclusions Our study demonstrated for the first time that hypoxia-induced enhancement of angiogenic capacity in cardiac ECs was inhibited in the presence of AGEs, which was related with downregulation of VEGF expression caused by ERK5 phosphorylation. Thus ERK5 may function as an important regulator in diabetes-induced impairment of angiogenesis and thereby exacerbated myocardial ischaemic injury through coordinately targeting VEGF in cardiac ECs. Intervention of ERK5 pathway mayrepresent an avenue for therapeutic exploitation to improve prognosis in diabetic individuals with coronary artery disease.

Angiopoietin-1 Protects the Endothelial Cells Against Advanced Glycation End Product Injury by Strengthening Cell Junctions and Inhibiting Cell Apoptosis

Erk And Akt Signaling Pathways Are Involved In Advanced Glycation End Product-Induced Autophagy In Rat Vascular Smooth Muscle Cells

Autophagy plays a protective role in advanced glycation end product-induced apoptosis of vascular endothelial cells

Autophagy protects against senescence and apoptosis via the RAS-mitochondria in high-glucose-induced endothelial cells.

AGEs Increased Migration and Inflammatory Responses of Adventitial Fibroblasts Via RAGE, MAPK and NF-κB Pathways

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Advanced Glycation End Products Facilitate Proliferation and Reduce Early Apoptosis of Cardiac Microvascular Endothelial Cell Via PKCβ Signaling Pathway: Insight from Diabetic Cardiomyopathy

Advanced Glycation End Products Upregulates The Expression Of Connexin43 Via Erk Mapk And Pi3k/Akt Pathways In Human Endothelial Cells

Advanced Glycation End Products Increased Angiopoietin-1 Expression Via Oxidative Stress and NF-κB Pathways in Cultured NRK-49F Cells

Glycation of Tie-2 Inhibits Angiopoietin-1 Signaling Activation and Angiopoietin-1-Induced Angiogenesis

Angiopoietin-1 Protects Mesenchymal Stem Cells Against Serum Deprivation and Hypoxia-Induced Apoptosis Through the PI3K/Akt Pathway

A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R-Dependent Glycolysis

Endothelial Intracellular ANG (Angiogenin) Protects Against Atherosclerosis by Decreasing Endoplasmic Reticulum Stress

GW24-e3729 ERK5 Mediates Advanced Glycation End Products-Induced Impairment of Angiogenic Capacity in Cardiac Endothelial Cells under Hypoxia Condition Through Regulation of VEGF Expression

Advanced glycation end products activated endothelial-to-mesenchymal transition in pancreatic islet endothelial cells and triggered islet fibrosis in diabetic mice

Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways

Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products.

Advanced Glycation End Products Impair Function of Late Endothelial Progenitor Cells Through Effects on Protein Kinase Akt and Cyclooxygenase-2

Advanced glycation end products induce endothelial hyperpermeability via β-catenin phosphorylation and subsequent up-regulation of ADAM10

Angiogenic Factor AGGF1-Primed Endothelial Progenitor Cells Repair Vascular Defect in Diabetic Mice

Inhibition of NA(+)/H(+) Exchanger 1 Attenuates Renal Dysfunction Induced by Advanced Glycation End Products in Rats.